E
GRI Bio, Inc. GRI
$2.31 $0.062.67% NASDAQ
Recommendation
Dividend Power Score
Prev Close
$2.25
Volume
33,312
Avg Vol (90D)
267,933
Market Cap
$3.25M
Dividend & Yield
--
52-Week Range
$2.10 - $311.36
P/E (TTM)
--
EPS (TTM)
-$248.16
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
Short Interest in GRI Bio, Inc. (NASDAQ:GRI) Decreases By 78.9%
2/11/2026 - Ticker Report
JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026
2/9/2026 - ACCESS Newswire
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
2/5/2026 - Globe Newswire
GRI Bio sees cash runway into 1Q27
2/4/2026 - TipRanks Financial Blog
GRI Bio sees cash runway into 1Q27
2/4/2026 - The Fly
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
2/4/2026 - Globe Newswire
Gri Bio Warns of Ongoing Internal Control Weaknesses That Could Threaten Financial Reporting Reliability and Investor Confidence
1/31/2026 - TipRanks Financial Blog
GRI Bio files $250M mixed securities shelf
1/30/2026 - The Fly
GRI Bio Reports Positive Study Results For Chronic Lung Disease, But Stock Slumps 20% What Happened?
1/28/2026 - Stocktwits News Feed
GRI Bio Inc trading resumes
1/28/2026 - TipRanks Financial Blog
GRI Bio Inc trading resumes
1/28/2026 - The Fly
GRI Bio Inc trading halted, volatility trading pause
1/28/2026 - The Fly
GRI Bio (GRI) Reports Promising Results from Latest IPF Study
1/28/2026 - GuruFocus
GRI Bio reports promising Phase 2a data in IPF
1/28/2026 - TipRanks Financial Blog
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key ...
1/28/2026 - GuruFocus
GRI Bio delivers additional data from Phase 2a study of GRI-0621
1/28/2026 - The Fly
GRI Bio delivers additional data from Phase 2a study of GRI-0621
1/28/2026 - The Fly
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
1/28/2026 - Globe Newswire
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures
1/26/2026 - GuruFocus
GRI Bio Secures New Patent for Immunomodulator Compounds
1/26/2026 - GuruFocus
GRI Bio secures U.S. composition of matter patent
1/26/2026 - The Fly
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures
1/26/2026 - Globe Newswire
GRI Bio Inc trading halted, news pending
1/24/2026 - TipRanks Financial Blog
GRI Bio Inc trading halted, news pending
1/24/2026 - The Fly
GRI Bio (NASDAQ:GRI) Shares Set to Reverse Split on Monday, January 26th
1/23/2026 - Ticker Report
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$11.97M
EBIT (TTM)
-$11.98M
Net Income (TTM)
-$11.96M
Balance Sheet
Total Assets (Q)
$8.67M
Total Debt (Q)
$71.00K
Total Liabilities (Q)
$2.66M
Book Value Per Share (Q)
$12.07
Cash Flow
Cash from Operations (TTM)
-$10.19M
Cash from Investing (TTM)
-$3.00K
Cash from Financing (TTM)
$13.39M
Net Change in Cash (TTM)
$3.20M
Filings
Filing Date
Friday, January 30, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of Mar 9 and 13 (est)
Price History
Loading...
Beta
2.47
7-Day Total Return
-12.50%
30-Day Total Return
-66.57%
60-Day Total Return
-94.84%
90-Day Total Return
-95.88%
Year to Date Total Return
-70.54%
1-Year Total Return
-99.10%
2-Year Total Return
-99.97%
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Feb 12, 2026 - $2.10
52-week High
Apr 01, 2025 - $311.36
Valuation
Market Cap
$3.25M - Nano Cap
Enterprise Value
-$4.91M
Price/Sales (TTM)
--
Price/Book (Q)
0.19
Dividends and Shares
Shares Outstanding
200.70K
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.gribio.com
Phone Number
619 400 1170
Address
2223 Avenida de la Playa
La Jolla, CA 92037
Country
United States
Year Founded
2009
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune... more
NASDAQ 02/13/2026 4:00PM Eastern Quotes delayed